Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
Application
US20260076921A1
Kind: A1
Mar 19, 2026
Inventors
Fotios M. PLAKOGIANNIS, Tamanna LATHER
Abstract
The present disclosure relates to the to the transdermal administration of THC and/or CBD and derivatives of these compounds, for the treatment and/or prevention and/or control of multiple sclerosis, multiple sclerosis-related muscle spasms, and pain and/or spasticity in multiple sclerosis.
CPC Classifications
A61K 9/7015
A61K 9/0021
A61K 9/7053
A61K 9/7061
A61K 9/7069
A61K 9/7084
A61K 31/137
A61K 31/277
A61K 31/658
A61P 25/28
Filing Date
2025-11-25
Application No.
19399983